Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply

Affiliations

Editorial

Pauline Wils et al. Aliment Pharmacol Ther. 2021 Feb.

. 2021 Feb;53(3):452-453.

doi: 10.1111/apt.16230.

No abstract available

Comment on

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Wils P, Seksik P, Stefanescu C, Nancey S, Allez M, Pineton de Chambrun G, Altwegg R, Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M, Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V, Laharie D, Pariente B; PREGNANCY-GETAID study group. Wils P, et al. Aliment Pharmacol Ther. 2021 Feb;53(4):460-470. doi: 10.1111/apt.16192. Epub 2020 Dec 7. Aliment Pharmacol Ther. 2021. PMID: 33345331
Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
Seow CH, Ma C. Seow CH, et al. Aliment Pharmacol Ther. 2021 Feb;53(3):450-451. doi: 10.1111/apt.16207. Aliment Pharmacol Ther. 2021. PMID: 33428251 No abstract available.

1. Seow CH, Ma C. Editorial: Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy. Aliment Pharmacol Ther. 2021;53:450-451..
1. Wils P, Seksik P, Stefanescu C, et al. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicenter cohort study. Aliment Pharmacol Ther 2020; in press. https://doi.org/10.1111/apt.16192
1. van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010;4:493-510.
1. Lichtenstein G, Cohen R, Feagan B, et al. Safety of infliximab in Crohn's disease: data from the 5000- patient TREAT Registry. Gastroenterology. 2004;126(Suppl 4):A54.
1. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.